Clinical trial
Influenza Immunity Against Pandemic Respiratory Virus
NCT00138281 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00138281 |
|---|---|
| Title | Influenza Immunity Against Pandemic Respiratory Virus |
| Official title | Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | FluMist, Fluzone |
| Enrollment | 60 |
| Primary completion | Nov 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Aug 30, 2005 |
| Last update posted | Aug 27, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: